Assessment of the Abbott BinaxNOW SARS-CoV-2 rapid antigen test against viral variants of concern

iScience

Kiran Verma¹  John Blackwood²  Anne L. Piantadosi²  Jessica Lin³  Anuradha Rao³  Kimberly Pachura³  Wilbur A. Lam³  Greg S. Martin³  Julie Sullivan³  Raymond Schinazi³  Leda Bassit³  Heather B. Bowers³  Morgan Greenleaf³  Eric Lai³  Thomas Pribyl⁴  Richard S. Creager⁵ 

[1] Georgia Institute of Technology, Atlanta, GA 30332, USA;BiocomX, Dana Point, CA 92629, USA;Emory University School of Medicine, Emory University, Room 448, Atlanta, GA 30322, USA;NaviDx, LLC, Newport Beach, CA 92660;Personalized Science, LLC, Burlington, VT, 05403;

关键词: Biological sciences;    Biotechnology;    Diagnostics;    Public health;    Virology;   

DOI  :  

来源: DOAJ

【 摘 要 】

Summary: As the emergence of SARS-CoV-2 variants brings the global pandemic to new levels, the performance of current rapid antigen tests against variants of concern and interest (VOC/I) is of significant public health concern. Here, we report assessment of the Abbot BinaxNOW COVID-19 Antigen Self-Test. Using genetically sequenced remnant clinical samples collected from individuals positive for SARS-CoV-2, we assessed the performance of BinaxNOW against the variants that currently pose public health threats. We measured the limit of detection of BinaxNOW against various VOC/I in a blinded manner. BinaxNOW successfully detected the Omicron (B.1.1.529), Mu (B.1.621), Delta (B.1.617.2), Lambda (C.37), Gamma (P.1), Alpha (B.1.1.7), Beta (B.1.351), Eta (B.1.525), and P.2 variants and at low viral concentrations. BinaxNOW also detected the Omicron variant in individual remnant clinical samples. Overall, these data indicate that this inexpensive and simple-to-use, FDA-authorized and broadly distributed rapid test can reliably detect Omicron, Delta, and other VOC/I.

【 授权许可】

Unknown